Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea FDA Unveils Initial Biosimilar Guidance; Final Guidelines To Be Released In July

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's FDA is putting the final touches on its EU-modeled initial guidelines for approval and registration of biosimilar products, and anticipates releasing a final version by the end of July
Advertisement

Related Content

Korea FDA Moving To Strengthen Pharmacovigilance - APEC Harmonization Center Asia Regulatory Conference
Korea FDA Moving To Strengthen Pharmacovigilance - APEC Harmonization Center Asia Regulatory Conference
Korea FDA Mulls Detailed Biosimilar Guidelines To Boost Homegrown Firms
Korea's Celltrion Completes Phase I Clinical Trials For Biosimilars Based On Roche And Johnson & Johnson Products
Demand For A/H1N1 Vaccine Catapults Green Cross Into No. 2 Spot In Korea; Company Ramps Up Biosimilar Pipeline
South Korea's Economy Minister Pledges Support for Local Biosimilar Companies
South Korea's Economy Minister Pledges Support For Local Biosimilar Companies
Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions
Korea FDA Gears Up To Release Biosimilar Guidelines Modeled After EU Rules
Korea FDA Gears Up To Release Biosimilar Guidelines Modeled After EU Rules
Advertisement
UsernamePublicRestriction

Register

SC072045

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel